Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Wednesday, July 8, 2009

Biogen wins speedy FDA review for MS drug

By Julie M. Donnelly

The U.S. Food and Drug Administration has granted “Fast-Track” status for a Biogen drug target for multiple sclerosis. Biogen is currently enrolling patients in a Phase 3 clinical trial for the drug, called PEGylated interferon beta-1a (BIIB017). The company plans to enroll 1,200 patients in the study.

The study will evaluate the efficacy and safety of either bi-weekly or once-monthly injections of PEGylated interferon beta-1a in this patient population. Many multiple sclerosis patients currently take weekly shots of medication.

The FDA’s Fast Track program is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs.

Biogen currently has two drugs on the market for the treatment of MS, Tysabri and Avonex. In June, the company’s stock dropped after news of a tenth patient taking Tysabri had been diagnosed with a potentially fatal brain infection called progressive multifocal leukoencephalopathy, or PML. In addition, on July 1, Biogen received the rights to commercialize a multiple sclerosis drug outside the U.S. from Acorda Therapeutics.

Biogen Idec stock (Nasdaq:BIIB) was trading at $45.33 in mid-morning trading on Wednesday, up from the previous close of $44.49 at the previous close.

 

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Comments

Please Login/Register to post comments.

No comments have been added or approved.

On the MHT blog now

Despite World Series, local algorithm helps jobless New Yorkers

NPR's Morning Edition reports on job counseling efforts at the state of New York's Department of Labor, and finds it's using an algorithm developed by Burning Glass Technologies, which is based in Quincy Market. Burning Glass develops algorithms that parse resume information and try to match job seekers with companies that will actually hire them. The job seeker in the story, a publishing i...

Read More

Most Popular Stories
EmailedViewed
Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
FinanceFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of, registration on, this site constitutes acceptance of our User Agreement. Please read our Privacy Policy (updated) A publishing partner with Portfolio